Multi-Modal Genomic Profiling
One integrated assay unifying DNA, RNA, and protein signals with AI interpretation — engineered for oncologists who need the complete biological picture before treatment.
Why Multi-Modal
DNA alone doesn't tell the full clinical story.
Mutation calls answer what changed. Multi-modal profiling answers what’s actually driving the tumor and what will respond to therapy.
Genomic mutations
- Detects mutations but misses expression context
- Blind to fusion events driving therapy response
- Cannot confirm protein-level biomarker activity
- Limited insight into tumor microenvironment
Integrated tumor biology
- DNA reveals actionable mutations and structural variants
- RNA confirms expression, splicing, and fusion drivers
- AI integrates all three into one clinical narrative
- DNA reveals actionable mutations and structural variants
Three Biological Dimension
Three orthogonal layers of tumor biology. One integrated report.
Genomics
DNA
Comprehensive detection of SNVs, indels, CNVs and structural variants across 1080+ oncology-relevant genes.
Clinical value
Identifies actionable variants and hereditary risk signatures.
Transcriptomics
RNA
Whole-transcriptome analysis capturing expression, alternative splicing and gene fusions.
Confirms functional impact and reveals fusion-driven therapy options.
Proteomics
Protein
Verifies eligibility for immunotherapy and antibody-drug conjugates.
Layered Intelligence
Three Levels of Tumor Understanding
WHAT
Alterations Present
Identify all genomic variants, mutations, and copy number changes across 1,080 genes
DRIVER
Cancer Drivers
Determine which alterations are actively driving tumor biology through RNA expression analysis
WHY
Biological Behavior
What the Report Delivers
Every finding written for the oncologist reading it.
One report. Six clinical answers. Every recommendation traceable to the underlying molecular evidence.
- Sample clinical report
Rev. 2025.1
Patient
F/54 · Lung adenocarcinoma · Stage IV
Tier IA · Actionable
EGFR L858R · Sensitizing mutation
Confirmed expression at 4.2× baseline
TMB
8.4
mut/Mb
PD-L1
45%
TPS
AI recommendation
Osimertinib first-line. Consider ctDNA monitoring at 8 weeks.
Matched trials
- NCT05920356 · Phase III
- NCT04988295 · Phase II
Actionable variants
Tier-graded findings with evidence-level annotation.
Therapy matching
On-label and off-label therapies mapped to biomarkers.
Clinical trials
Regionally filtered, actively enrolling matches.
Drug resistance
Known and emerging resistance markers surfaced.
Biomarker summary
TMB, MSI, PD-L1, HRD and pathway scores.
AI clinical insights
Contextual narrative with citation-backed rationale.
Platform Specifications
Engineered for clinical-grade performance.
1080+
Cancer-relevant genes
Curated panel spanning solid tumors and hematologic malignancies.
200×+
Sequencing depth
Deep coverage for confident low- frequency variant calling.
50
Actionable biomarkers
IHC, expression and signature- based clinical markers.
38
Cancer types validated
Analytically and clinically validated across major indications.
Assay workflow
Sample to clinical answer in 10 days
Turnaround
10 days
Sensitivity
>99%
Sample
FFPE / Blood
When to Deploy
Clinical decision support at ordering time.
Match the assay to the clinical question. Multi-modal isn’t always the answer — we’ll tell you when it is.
- Recommended
Deploy multi-modal profiling
- Advanced or metastatic solid tumors
- Rare cancers with limited standard of care
- Suspected fusion-driven malignancies
- Immunotherapy candidacy evaluation
- Consider Carefully
Weigh clinical benefit
- Very early-stage tumors with clear standard of care
- Patients not eligible for systemic therapy
- When rapid targeted panel already sufficient
- Alternative Testing
Prefer focused assays
- Single hotspot mutation confirmation
- MRD monitoring — use ctDNA assay
- Hereditary risk screening only
Case Study
Poorly differentiated gastric adenocarcinoma
How multi-modal profiling changed the treatment path when standard testing was inconclusive.
Clinical summary
M/62 · Stage IV · Prior IHC inconclusive
Patient timeline
- Day 0 Presentation with poorly differentiated gastric adenocarcinoma
- Day 3 FFPE block received; multi-modal profiling initiated
- Day 12 Report delivered: HER2 amplification + FGFR2 fusion detected
- Day 18 Trastuzumab deruxtecan initiated; enrolled in FGFR2 trial
Biomarker findings
HER2
Amplified · 8.2×
FGFR2
BICC1-FGFR2 fusion
MSI
Stable
PD-L1
CPS 12
TMB
6.1 mut/Mb
Treatment outcome
Response at 12 weeks vs standard chemotherapy
Recommendation applied
Trastuzumab deruxtecan (T-DXd) with FGFR inhibitor trial enrollment — enabled only by combined DNA + RNA analysis.
39pp
ORR gain
2.4×
PFS extension
Tier IA
Evidence
Product Comparison
How OncoIndx compares to conventional profiling.
Gene coverage
~50 genes
500+ genes
SNVs & indels
CNVs & structural variants
Trial & therapy matching
Why Choose OncoIndx
Built with oncologists. Validated against outcomes.
OncoIndx Multi-Modal is engineered around the questions oncology teams ask at the tumor board — not the biomarkers a technology happens to measure.
CAP Accredited
CLIA Certified
AI Governance
Comprehensive
DNA, RNA, and protein signals interrogated from a single sample.
AI Guided
Interpretation trained on curated oncology cohorts and literature.
Evidence Based
Every recommendation tier-graded and citation-backed.
Actionable
Prioritized therapies and trials matched to your patient.
See the complete clinical picture.
Empower confident treatment decisions with integrated multi-modal profiling — purpose-built for the oncologists making them.
Access OncoIndx Multi-Modal Sample Reports & Case Studies
Fill in your details to explore real-world oncology insights…
Access OncoIndx Multi-Modal Sample Reports & Case Studies
Fill in your details to explore real-world oncology insights…